Patients With Schizophrenia Twice as Likely to Develop Dementia?

Patients with psychotic disorders such as schizophrenia are more than twice as likely as those without a psychotic disorder to eventually develop dementia, new research suggests. Results from a review and meta-analysis of almost 13 million total participants from nine countries showed that, across multiple different psychotic disorders, there was a 2.5-fold higher risk of … Read more

Menopause an Independent Risk Factor for Schizophrenia Relapse?

Menopause appears to be an independent risk factor for relapse in women with schizophrenia spectrum disorders (SSDs), new research suggests. Investigators studied a cohort of close to 62,000 people with SSDs, stratifying individuals by sex and age, and found that starting between the ages of 45 and 50 years — when the menopausal transition is … Read more

‘Amazing’ Phase 3 Results for Novel Schizophrenia Combo Drug

VIENNA — The investigational agent xanomeline-trospium (KarXT, Karuna Therapeutics) achieves significant and clinically meaningful improvements in schizophrenia symptom scores without causing problematic adverse effects, new research suggests. Results from the phase 3 EMERGENT-2 trial, which included more than 250 patients with schizophrenia, showed that those who received xanomeline-trospium for 5 weeks achieved a significant reduction … Read more

Antibiotic May Enhance TMS, Improve Depression Outcomes

Administering D-cycloserine (DCS) along with transmagnetic stimulation (TMS) may be a promising strategy to improve outcomes in major depressive disorder (MDD), new research suggests. “The take-home message is that this proof-of-concept study opens up a new avenue of treatment research so that in the future, we may be able to provide our patients with safe … Read more

Suicide Notes Are ‘Unique Window’ Into Motives, Risks in the Elderly

Suicide notes left by elderly people provide a unique opportunity to better understand and prevent suicide in this often vulnerable population. A new analysis of notes penned by seniors who died by suicide reveals several common themes. These include feeling as if they were a burden, feelings of guilt, experiencing mental illness, loneliness, or isolation, … Read more

Schizophrenia, Postmodernism: A Philosophical Treatment Exercise

Schizophrenia is defined as having episodes of psychosis: periods of time when one suffers from delusions, hallucinations, disorganized behaviors, disorganized speech, and negative symptoms. The concept of schizophrenia can be simplified as a detachment from reality. Patients who struggle with this illness frame their perceptions with a different set of rules and beliefs than the … Read more

California Governor OKs Mental Health Courts for Homeless

SAN FRANCISCO (AP) — With more than 100,000 people living on California’s streets, Gov. Gavin Newsom signed a first-of-its kind law on Wednesday that could force some of them into treatment as part of a program he describes as “care” but opponents argue is cruel. Newsom signed the Community Assistance, Recovery and Empowerment Act on … Read more

Baseline Neuromotor Abnormalities Persist in Schizophrenia

Baseline dyskinesia and neurological soft signs (NSS) predicted the disease process of schizophrenia over a 21-year follow-up period, based on data from 243 adult patients. Neuromotor abnormalities in psychotic disorders have long been ignored as side effects of antipsychotic drugs, but they are gaining new attention as a component of the disease process, with implications … Read more

Subtle Visual Dysfunctions Often Precede Early-Stage Psychosis

Subtle subjective visual dysfunctions (VisDys) are common and are associated with poorer outcomes of patients with schizophrenia and recent-onset psychosis or who are at clinical high risk (CHR) for psychosis, new research suggests. A multinational group of investigators found that said Vis-more often by patients with recent onset psychosis and CHR than by those with … Read more

Positive Phase 3 Results for Novel Schizophrenia Drug

The investigational agent xanomeline-trospium (KarXT, Karuna Therapeutics), which combines a muscarinic receptor agonist with an anticholinergic agent, helps improve psychosis symptoms, and is not associated with weight gain or sedation in adults with schizophrenia, new research shows. Top-line results from the phase 3 EMERGENT-2 trial showed a significantly greater reduction from baseline on Positive and … Read more